MEDIUM confidence: 100% data completeness, but the composite (56) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $170 avg across 8 analysts.
Buy-rated share 67% → 65% over ~3 months (-2pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $1.68 | $1.71 | +1.8% |
| May 2026 | $1.53 | $1.54 | +0.7% |
| Feb 2026 | $1.42 | $1.46 | +2.8% |
| Nov 2025 | $1.62 | $1.62 | +0.0% |
| Aug 2025 | $1.51 | $1.52 | +0.7% |
| May 2025 | $1.41 | $1.48 | +5.0% |
| Feb 2025 | $1.28 | $1.38 | +7.8% |
| Nov 2024 | $1.47 | $1.48 | +0.7% |
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 5.0%/yr (revenue basis).
Base free cash flow $2.0B (avg FY2023–FY2025; latest year $2.7B) · equity value $91.4B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $12.9B— | $13.8B+6.7% | $15.2B+9.9% | $17.5B+15.3% | $18.0B+3.0% |
| EPS (dil.) | $3.83— | $4.60+20.3% | $3.73-19.0% | $3.43-8.0% | $4.04+17.8% |
| Free Cash Flow | $3.0B— | $2.4B-20.1% | $274M-88.5% | $2.9B+963.1% | $2.7B-8.4% |
| Gross Margin | 44.3% | 45.7%+1.4pp | 49.0%+3.3pp | 50.8%+1.8pp | 52.8%+2.0pp |
| Operating Margin | 15.1% | 17.1%+1.9pp | 18.2%+1.1pp | 15.2%-3.0pp | 19.6%+4.4pp |
| Net Margin | 17.8% | 23.4%+5.6pp | 87.2%+63.8pp | 11.3%-75.9pp | 12.7%+1.5pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$4.4M over 180 days (0 open-market buys, 3 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 56 for EMR suggests a neutral outlook, with the stock's short-term and long-term scores relatively aligned. EMR scores high on momentum, driven by its 20% return over the past year, and risk, with a relatively low beta of 1.2. However, the stock trades at a premium, with a P/E of 35.7, which weighs on its value score, and its growth score is also subdued due to negative free cash flow growth. Overall, EMR exhibits strong momentum but is held back by its valuation and mixed growth profile.